BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXL) (TSX: BCT) reported that its Phase 3 Bria-ABC study has enrolled over 230 patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE